CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

Punjadath et al. Predictors of progression palindromic rheumatism to RA. 30 patients. 47% progressed to RA. Total number of joints involved, RF, CRP predicted progression univariate. Only total joints significant in mutlivariate but underpowered. @RheumNow #ACR25 Abstr#2261 https://t.co/FtVKdGtEr9

Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi

Can fiber make methotrexate work better? (LB15) In a placebo-controlled Superfibers RCT, inulin 12 g/day improved EULAR response & Th17/Treg ratio in RA among MTX users. @RheumNow #ACR25 https://t.co/awMRNloNw5

Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy RCT of 119 pt 57.1% response at wk 28 in SEC 27% response at wk 28 in UST Numerically lower adverse events leading to d/c in SEC @RheumNow #ACR25 #ACRBest Abst LB06 https://t.co/wDxtscP2ku

Does fiber boost MTX efficacy? LB15: Fiber + MTX led to 📉 Greater drop in DAS28 (–1.00 vs –0.34 placebo) 🧬 ↓ Th17 cells & Th17/Treg ratio Some food for thought @RheumNow #ACR25 https://t.co/VhLVP1nRy2

Serrano-Combarro et al. Baricitinib in RA-ILD. Observational, 42 patients. Progressive ILD in 26%. More frequent in women. @RheumNow #ACR25 Abstr#2229 https://t.co/ZXfgxKoau7

Benson et al. Clinical features that predict CV risk in PsA. Median 3.53 year follow up. 56 CV events. 766 patients. Dactylitis emerged as key predictor in adjusted models. @RheumNow #ACR25 Abstr#2317 https://t.co/5O3G7vGYbq

Cutaneous vasculitis: who is most likely to have systemic disease? 430 pt w skin vasculitis examined in case-control Associated with risk for systemic vasculitis/CTD: - GI sx - ulcerating/necrotic lesions - constitutional sx - hematuria @RheumNow #ACR25 Abst 2525 https://t.co/lRjLKRYxDW

How great would it be to have a diagnostic RA-ILD Urine Dipstick? Small cohort 14 RA-ILD vs. 64 RA no ILD Urine ILDScore includes 2 proteins SPOCK1 and PGRMC1 Independently asso with ILD w/ OR 6.19 Urine ILD score alone AUC 0.9 ILD urine score + clinical data AUC = 0.95 Needs https://t.co/7PqX8kdjKJ

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

Interesting study evaluating the "CALLY" index (serum albumin × lymphocyte count / CRP / 10,000) for predicing mortality in AAV I typically dislike these because (1) they are often cumbersome to calculate & (2) they often perform poorly This one piqued my interest; pretty https://t.co/ziroQOH5Cq